Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145507 | 1.00 | ALDH1A1 (0.64) | ALDH1A1KDM4EHSD17B10HPGDENPP2 | |
| Hydrochloric Acid SCHEMBL28263913 | 0.98 | ALDH1A1 (0.62) | ALDH1A1KDM4EHSD17B10HPGDENPP2 | |
| Acetic Acid SCHEMBL28248344 | 0.95 | ALDH1A1 (0.63) | ALDH1A1KDM4EHSD17B10HPGDENPP2 | |
| SCHEMBL28247653 | 0.94 | KDM4E (0.57) | ALDH1A1KDM4EHSD17B10HPGDENPP2 | |
| SCHEMBL29983717 | 0.90 | ALDH1A1 (0.53) | ALDH1A1KDM4EHSD17B10HPGDENPP2 | |
| SCHEMBL29377304 | 0.86 | TUBB4A (0.58) | TAS1R3TAS1R1CDK8NPC1MAPT | |
| SCHEMBL103794 | 0.86 | TUBB4A (0.58) | TAS1R3TAS1R1CDK8NPC1MAPT | |
| SCHEMBL28109570 | 0.85 | KDM4E (0.55) | ALDH1A1KDM4EHSD17B10HPGDENPP2 | |
| Ammonia Solution, Strong SCHEMBL28339305 | 0.85 | TUBB4A (0.57) | TAS1R3TAS1R1CDK8NPC1MAPT | |
| Hydrochloric Acid SCHEMBL28263909 | 0.85 | TUBB4A (0.57) | TAS1R3TAS1R1CDK8NPC1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026002524-A1 | ANTICORROSION LIQUIDS | WOCKLAB GMBH & CO. KG (DE) | 2026-01-02 | — | — | WO | disclosed |
| CN-119278034-A | Selective histone deacetylase 8 (HDAC 8) degradants and methods of use thereof | 丹娜-法伯癌症研究院 | 2025-01-07 | — | — | CN | disclosed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11802131-B2 | Glutarimides for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023009330-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802131-B2 | Glutarimides for medical treatment | CRBN, GCDH, GCLC | ALDH1A1 1593/4885KDM4E 831/4885HSD17B10 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.